European Commission grants J&J, Celgene blood cancer approvals

Celgene

The European Commission was good to blood cancer drugmakers this week, granting multiple myeloma approvals for Johnson & Johnson's ($JNJ) Velcade and Celgene's ($CELG) Imnovid. While Velcade was already approved for certain multiple myeloma cases, the new guidance will open up its market to cover earlier use in the cancer. Velcade, in combination with certain other drugs, can now be used as a first-line treatment option for adults. Velcade is one of the drugs that J&J has been pushing for line extensions to boost revenue while it builds out products in its pipeline. Imnovid's approval is more limited in scope: It covers use of the drug in adult patients who have received at least two prior therapies and still demonstrated disease progression. 

Read more on

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.